It is suitable for the treatment of patients with chronic lymphocytic leukemia and refractory or recurrent deletion of 17p mutant gene.
1. Adult patients with chronic lymphocytic leukemia (CLL) who have 17p deletion mutations or TP53 mutations and are not suitable or have received b-cell receptor signaling inhibitors but have failed treatment;
2. Adult patients with chronic lymphocytic leukemia (CLL) who do not have 17p deletion mutations or TP53 mutations and who have previously failed chemotherapy-immunotherapy and b-cell receptor signaling pathway inhibitors.
We provide customers with quality products and services.
If you would like to leave us a comment please go to contact us